Facebook
Twitter
LinkedIn
ForwardFine Tuning our Antimicrobials: Navigating Therapeutic Drug Monitoring and Optimizing Administration Strategies - On Demand
In the last several months, new recommendations have been published on therapeutic drug monitoring for triazole antifungals, as have international consensus guidelines on the prolonged infusion of beta-lactams. Additionally, a wealth of knowledge has been published over the last decade regarding TDM for linezolid. While linezolid has long been thought to be a drug which does not require dose adjustment, current evidence clearly suggests that TDM with subsequent dose adjustments should be considered standard of care. This presentation will review the new data on triazoles/beta-lactams and will help clinicians establish a program for routine TDM for patients receiving linezolid.
Target Audience
Pharmacist
Learning Objectives
1. Summarize contemporary literature for beta-lactam therapeutic drug monitoring (TDM) and identify optimal administration strategies/appropriate patients for TDM
2. Describe the need for linezolid TDM and develop strategies for implementing a successful TDM program
3. Review approaches to triazole TDM and explain strategies for administering crushed posaconazole tablets/opened isavuconazole capsules
Additional Information
| Attachment | Size |
|---|---|
 Helpful Tips for Users - Vizient CE System.pdf | 134.81 KB |
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
Kate DeSear, PharmD, BCIDP, AAHIVP, FIDSA (see below - All relationships have ended)
Name of Ineligible Company | Nature of Financial Relationship |
Shionogi | Advisor |
Spero | Advisor |
Melinta | Advisor |
Entasis | Advisor |
Abbvie | Advisor |
Basilea | Advisor |
All relevant financial relationships listed for these individual(s) have been mitigated.
All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Faculty
Kate DeSear, PharmD, BCIDP, AAHIVP, FIDSA
Clinical Specialist, Infectious Diseases | Department of Pharmacy
Clinical Assistant Professor | University of Florida College of Pharmacy
Ethan A. Smith, PharmD, BCIDP
Ronald Reagan UCLA Medical Center
Planning committee
Gretchen Brummel, PharmD, BCPS (Course Director)
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence
Vizient, Inc.
Jackie Stokes, BBA
Manager, Pharmacy Program
Vizient, Inc.
John Schoen, PharmD, BCPS
Senior Clinical Manager
Vizient, Inc.
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statement(s):
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number:JA0006103-0000-23-344-H01-P
OTHER
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re- certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 General CE – Attendance